New drug combo aims to tame inflammation before stem cell transplant

NCT ID NCT05787574

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests whether giving emapalumab or a combination of fludarabine and dexamethasone before a stem cell transplant can reduce inflammation and help the donated cells take hold better. The trial involves 39 people with primary immune regulatory disorders or autoinflammatory conditions. Researchers will measure how well the stem cells engraft and track overall survival and event-free survival after the transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Emapalumab (also called Gamifant), fludarabine, and dexamethasone

What this could lead to

If it works, this could point toward a safer way to prepare patients with immune disorders for a stem cell transplant, reducing inflammation and improving the chance of a successful transplant.

What could go wrong

This is a small, early-phase trial with only 39 participants, so results may not apply to everyone. The treatments also carry risks like infection or side effects from the drugs and transplant procedure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE SYSTEM DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune lymphoproliferative syndrome autoinflammatory syndrome immune system disorder inborn error of immunity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Healthcare of Atlanta

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-••••

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-••••

  • Children's Hospital of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

    Contact Phone: •••-•••-••••

  • Columbia University Irving Medical Center

    RECRUITING

    New York, New York, 10032, United States

  • Memorial Sloan Kettering Basking Ridge

    ACTIVE_NOT_RECRUITING

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen

    ACTIVE_NOT_RECRUITING

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    ACTIVE_NOT_RECRUITING

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Monmouth

    ACTIVE_NOT_RECRUITING

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    ACTIVE_NOT_RECRUITING

    Rockville Centre, New York, 11553, United States

  • Memorial Sloan Kettering Suffolk - Commack

    ACTIVE_NOT_RECRUITING

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Westchester

    ACTIVE_NOT_RECRUITING

    Harrison, New York, 10604, United States

  • Texas Children's Hospital

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-••••

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Phone: •••-•••-••••